

AAP Pediatric Obesity Clinical Support Chart

Author

American Academy of Pediatrics
Section on Obesity

Editors

Sarah Armstrong, MD, FAAP
Victoria Rogers, MD, FAAP
Mona Sharifi, MD, MPH, FAAP



American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®



Special thanks to Jeanne Lindros, Director, Institute for Healthy Childhood Weight,
for her invaluable support in creating this resource.

American Academy of Pediatrics Publishing Staff

Mary Lou White, *Chief Product and Services Officer/SVP, Membership, Marketing, and Publishing*

Mark Grimes, *Vice President, Publishing*

Heather Babiar, MS, *Senior Editor, Professional/Clinical Publishing*

Caroline Heller, PhD, *Editorial Assistant*

Jason Crase, *Senior Manager, Production and Editorial Services*

Shannan Martin, *Production Manager, Consumer Publications*

Peg Mulcahy, *Manager, Art Direction and Production*

Mary Louise Carr, MBA, *Marketing Manager, Clinical Publications*

Published by the American Academy of Pediatrics

345 Park Blvd

Itasca, IL 60143

Telephone: 630/626-6000

Facsimile: 847/434-8000

www.aap.org

The American Academy of Pediatrics is an organization of 67,000 primary care pediatricians, pediatric medical subspecialists, and pediatric surgical specialists dedicated to the health, safety, and well-being of all infants, children, adolescents, and young adults.

While every effort has been made to ensure the accuracy of this publication, the American Academy of Pediatrics does not guarantee that it is accurate, complete, or without error.

The recommendations in this publication do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

Any websites, brand names, products, or manufacturers are mentioned for informational and identification purposes only and do not imply an endorsement by the American Academy of Pediatrics (AAP). The AAP is not responsible for the content of external resources. Information was current at the time of publication.

The persons whose photographs are depicted in this publication are professional models. They have no relation to the issues discussed. Any characters they are portraying are fictional.

The publishers have made every effort to trace the copyright holders for borrowed materials. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.

This publication has been developed by the American Academy of Pediatrics. The contributors are expert authorities in the field of pediatrics. No commercial involvement of any kind has been solicited or accepted in the development of the content of this publication. Disclosures: The editors disclosed no relevant financial relationships.

Every effort has been made to ensure that the drug selection and dosages set forth in this publication are in accordance with the current recommendations and practice at the time of publication. It is the responsibility of the health care professional to check the package insert of each drug for any change in indications or dosage and for added warnings and precautions.

Every effort is made to keep the *AAP Pediatric Obesity Clinical Support Chart* consistent with the most recent advice and information available from the American Academy of Pediatrics.

Please visit www.aap.org/errata for an up-to-date list of any applicable errata for this publication.

Special discounts are available for bulk purchases of this publication. Email Special Sales at nationalaccounts@aap.org for more information.

© 2024 American Academy of Pediatrics

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means—electronic, mechanical, photocopying, recording, or otherwise—without prior permission from the publisher (locate title at <https://publications.aap.org/aapbooks> and click on © Get Permissions; you may also fax the permissions editor at 847/434-8780 or email permissions@aap.org).

Printed in the United States of America

1 2 3 4 5 6 7 8 9 10

MA1099

ISBN: 978-1-61002-674-1

eBook: 978-1-61002-675-8

Cover and publication design by Peg Mulcahy

Author

American Academy of Pediatrics (AAP) Section on Obesity

Editors

Sarah Armstrong, MD, FAAP, Chair, AAP Section on Obesity, Co-director of the Duke Center for Childhood Obesity, and Professor of Pediatrics and Population Health Sciences, Duke University, Durham, NC

Victoria Rogers, MD, FAAP, Associate Director, AAP Institute of Healthy Childhood Weight, Medical Director of Let's Go!, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, ME, and Associate Clinical Professor of Pediatrics, Tufts University School of Medicine, Boston, MA

Mona Sharifi, MD, MPH, FAAP, Associate Professor of Pediatrics (General Pediatrics) and Biostatistics (Health Informatics), Director of the Yale Scholars in Implementation Science K12 Program, and Co-director of the National Clinician Scholars Program, Yale University, New Haven, CT

Equity, Diversity, and Inclusion Statement

The American Academy of Pediatrics is committed to principles of equity, diversity, and inclusion in its publishing program. Editorial boards, author selections, and author transitions (publication succession plans) are designed to include diverse voices that reflect society as a whole. Editor and author teams are encouraged to actively seek out diverse authors and reviewers at all stages of the editorial process. Publishing staff are committed to promoting equity, diversity, and inclusion in all aspects of publication writing, review, and production.

Introduction

The purpose of this resource is to summarize and highlight the clinical recommendations in the American Academy of Pediatrics (AAP) 2023 "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity" and to facilitate integration of key recommendations into everyday clinical practice. Obesity is a complex and chronic disease, and these reference tools have been gathered and are provided in this chart as supports to help you in your approach to pediatric care. Pediatricians and other pediatric health care providers are encouraged to read the clinical practice guideline (CPG) and related reports for full context and comprehension, available at www.aap.org/obesityCPG.

This chart focuses on a holistic approach to assessing and evaluating children and adolescents with obesity, and it covers comprehensive longitudinal treatment for patients with overweight or obesity. Key content and resources have been included for your reference and use, including a series of resources that highlight the overarching CPG guidance.

These resources include the AAP Key Action Statements, the AAP Consensus Recommendations, and the Algorithm for Pediatric Overweight and Obesity (*see Evidence and Recommendations*), which will help you get an overall picture of the recommendations and how they relate to each other.

This chart also features a deeper dive into the related CPG content associated with obesity (Evidence and Recommendations, Evaluation [for Primary Well-Child Visits], Treatment [for Obesity Follow-up and Sick Visits], and Office Resources, Supports, and Operations) in the tabs that follow.

We hope you find the AAP Pediatric Obesity Clinical Support Chart to be beneficial and useful in your practice.

"Pediatricians and other PHCPs now have more evidence-based tools than ever before to deliver obesity treatment that is effective, provides ongoing health benefits, supports children and families longitudinally, and reduces potential harms for disordered eating."

— "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity"

Contents

Evidence and Recommendations	
1. AAP Key Action Statements	1
2. AAP Consensus Recommendations	3
3. Algorithm for Pediatric Overweight and Obesity	4
Evaluation (for Primary Well-Child Visits)	
4. Evaluation	5
5. Stigma and Communication	6
6. Clinical Flow: Assessment and Evaluation	7
7. Risk	9
8. Physical Examination Findings	12
9. Commonly Prescribed Medications and Weight Gain	15
10. Conditions That Occur With Obesity	17

Treatment (for Obesity Follow-up and Sick Visits)	
11. Treatment	18
12. Treatment in the Primary Care Office	19
13. Intensive Health Behavior and Lifestyle Treatment	23
14. My Goal Sheets	26
Office Resources, Supports, and Operations	
15. Operationalizing Care	28
16. Welcoming Office	29
17. Capacity Considerations	31
18. Coding for Overweight and Obesity	34
19. 5210 Healthy Habits Questionnaire (Ages 2–9)	36
20. 5210 Healthy Habits Questionnaire (Ages 10+)	38

1. AAP Key Action Statements

Key Action Statement No.	Action	Evidence Quality and Strength
KAS 1	Pediatricians and other PHCPs should measure height and weight, calculate BMI, and assess BMI percentile using age- and sex-specific CDC growth charts or growth charts for children with severe obesity at least annually for all children 2 to 18 years of age to screen for overweight (BMI \geq 85th percentile to $<$ 95th percentile), obesity (BMI \geq 95th percentile), and severe obesity (BMI \geq 120% of the 95th percentile for age and sex).	Grade B, Moderate
KAS 2	Pediatricians and other PHCPs should evaluate children 2 to 18 years of age with overweight (BMI \geq 85th percentile to $<$ 95th percentile) and obesity (BMI \geq 95th percentile) for obesity-related comorbidities by using a comprehensive patient history, mental and behavioral health screening, SDoH evaluation, physical examination, and diagnostic studies.	Grade B, Strong
KAS 3	In children 10 years and older, pediatricians and other PHCPs should evaluate for lipid abnormalities, abnormal glucose metabolism, and abnormal liver function in children and adolescents with obesity (BMI \geq 95th percentile) and for lipid abnormalities in children and adolescents with overweight (BMI \geq 85th percentile to $<$ 95th percentile).	Grade B, Strong
KAS 3.1	In children 10 years and older with overweight (BMI \geq 85th percentile to $<$ 95th percentile), pediatricians and other PHCPs may evaluate for abnormal glucose metabolism and liver function in the presence of risk factors for TD2M or NAFLD. In children 2 to 9 years of age with obesity (BMI \geq 95th percentile), pediatricians and other PHCPs may evaluate for lipid abnormalities.	Grade C, Moderate
KAS 4	Pediatricians and other PHCPs should treat children and adolescents for overweight (BMI \geq 85th percentile to $<$ 95th percentile) or obesity (BMI \geq 95th percentile) and comorbidities concurrently.	Grade A, Strong
KAS 5	Pediatricians and other PHCPs should evaluate for dyslipidemia by obtaining a fasting lipid panel in children 10 years and older with overweight (BMI \geq 85th to $<$ 95th percentile) and obesity (\geq 95th percentile) and may evaluate for dyslipidemia in children 2 through 9 years of age with obesity.	Grade B: Children \geq 10 years of age with obesity, Strong; Grade C: Children 2–9 years of age with obesity, Moderate
KAS 6	Pediatricians and other PHCPs should evaluate for prediabetes and/or diabetes mellitus with fasting plasma glucose, 2-hour plasma glucose after 75-g oral glucose tolerance test, or glycosylated hemoglobin level.	Grade B, Moderate
KAS 7	Pediatricians and other PHCPs should evaluate for NAFLD by obtaining an alanine transaminase level.	Grade A, Strong
KAS 8	Pediatricians and other PHCPs should evaluate for hypertension by measuring blood pressure at every visit, starting at 3 years of age, in children and adolescents with overweight (BMI \geq 85 to $<$ 95th percentile) and obesity (BMI \geq 95th percentile).	Grade C, Moderate
KAS 9	Pediatricians and other PHCPs should treat overweight (BMI \geq 85 to $<$ 95th percentile) and obesity (BMI \geq 95th percentile) in children and adolescents by following the principles of the medical home and the chronic care model and by using a family-centered and nonstigmatizing approach (<i>see “5. Stigma and Communication”</i>) that acknowledges the biological, social, and structural drivers of obesity.	Grade B, Strong

Key Action Statement No.	Action	Evidence Quality and Strength
KAS 10	Pediatricians and other PHCPs should use motivational interviewing (<i>see “12. Treatment in the Primary Care Office”</i>) to engage patients and families when treating overweight (BMI ≥ 85 to <95th percentile and obesity (BMI ≥ 95th percentile).	Grade B, Moderate
KAS 11	Pediatricians and other PHCPs should provide or refer children 6 years and older (Grade B) and may provide or refer children 2 through 5 years of age (Grade C) with overweight (BMI ≥ 85 to <95th percentile) and obesity (BMI ≥ 95th percentile) to intensive health behavior and lifestyle treatment (<i>see “13. Intensive Health Behavior and Lifestyle Treatment”</i>). Health behavior and lifestyle treatment is more effective with greater contact hours; the most effective treatment includes 26 or more hours of face-to-face, family-based, multicomponent treatment over a 3- to 12-month period.	Grade B: Children ≥ 6 years of age with overweight and obesity, Moderate; Grade C: Children 2–5 years of age with overweight and obesity, Moderate
KAS 12	Pediatricians and other PHCPs should offer weight loss pharmacotherapy (<i>see “12. Treatment in the Primary Care Office”</i>) to adolescents 12 years and older with obesity (BMI ≥ 95th percentile), according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment.	Grade B, Moderate
KAS 13	Pediatricians and other PHCPs should offer referral for adolescents 13 years and older with severe obesity (BMI ≥ 120% of the 95th percentile for age and sex) for evaluation for metabolic and bariatric surgery to local or regional comprehensive multidisciplinary pediatric metabolic and bariatric surgery centers.	Grade C, Moderate

Notes: Per KAS 3 and 3.1: Pediatricians and other PHCPs should evaluate children 10 years and older with obesity (BMI ≥ 95th percentile) for abnormal glucose metabolism and may evaluate children 10 years and older with overweight (BMI ≥ 85th percentile to <95th percentile) with risk factors for T2DM or NAFLD for abnormal glucose metabolism.

Per KAS 3 and 3.1: Pediatricians and other PHCPs should evaluate children 10 years and older with obesity (BMI ≥ 95th percentile) for abnormal liver function and may evaluate children 10 years and older with overweight (BMI ≥ 85th percentile to <95th percentile) with risk factors for T2DM or NAFLD for abnormal liver function.

BMI, body mass index; CDC, Centers for Disease Control and Prevention; KAS, key action statement; NAFLD, nonalcoholic fatty liver disease; PHCP, pediatric health care provider; SDoH, social determinant of health; T2DM, type 2 diabetes mellitus.

Adapted from Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. *Pediatrics*. 2023;151(2):e2022060640.